Sand Hill Angels, Inc.

BiPar Sciences Co-Founder Allan Basbaum Honored with Membership in Royal Society

BiPar Sciences, Inc. announced today that Allan Basbaum, Ph.D., chairman of the Department of Anatomy at the University of California-San Francisco, BiPar's co-founder and a member of the company's scientific advisory board, was elected to the Royal Society, the United Kingdom's national academy of sciences.

Pathwork Diagnostics Formed From Venture-Backed Acquisition

With new venture capital funding, Predicant Biosciences has acquired San Jose-based Pathwork Informatics and named the merged company Pathwork Diagnostics, the new corporation announced today. Financial details were not disclosed. The new company will develop and commercialize innovative genomic diagnostic tests for oncology.

BiPar Sciences Accelerates Clinical Program With New Financing

BiPar Sciences, Inc., a privately-held biopharmaceutical company focused on novel therapeutics for cancer, announced today it has secured a $5 million venture debt commitment from Lighthouse Capital Partners. The company plans to use the funding to accelerate and expand the clinical program for its lead compound, BSI-201, and move two additional compounds toward clinical development.

Magnolia Broadband's DiversityPlus named to EDN's Hot 100 Products of 2005

Congratulations to Magnolia Broadband, whose DiversityPlus smart antenna chips for mobile devices were named to EDN's Hot 100 Products of 2005.

Sand Hill Angels at the IBF Venture Capital Investing Conference

Sand Hill Angels is a sponsor of the IBF Venture Capital Investing Conference, to be held on June 7 -9, 2006, in San Francisco. Steve Stephansen is a panelist on "The Changed Face of Early Stage Investing".

BiPar Sciences, Inc. Announces Start Of Phase 1 Clinical Trial For BSI-201

BiPar Sciences, Inc., a privately-held biopharmaceutical company focused on novel therapeutics for cancer, announced today that the Company has opened enrollment into a Phase I clinical trial of its lead compound, BSI-201, for patients with advanced malignancies. BSI-201 is the first of a new class of cancer therapies that selectively induces tumor cell death by inhibiting enzyme function central to tumor survival.

Affymetrix and PathWork Informatics Forge Collaboration to Develop New Cancer Diagnostics

Affymetrix Inc. (Nasdaq:AFFX) and PathWork Informatics Inc. announced today that Affymetrix has granted PathWork long-term non-exclusive access to its microarray technology to develop and market in-vitro diagnostic tests for cancer. Under the agreement, PathWork has the right to use Affymetrix microarray technology for the development of tests for cancer of unknown primary, as well as the option to develop other cancer tests. The resulting microarray products would enable clinicians to provide more efficient and complete methods to diagnose, classify and manage cancer.

BiPar Sciences closes $12.5M Series A

Round led by Vulcan Capital in syndication with Canaan Partners, Asset Management, Polytechnos Venture Partners and Quantum Technology Partners. BiPar to develop PARP inhibitor for cancer treatments.

Intelleflex closes $11.3 million Series A

Round was co-led by Alloy Ventures, Selby Ventures and Woodside Fund. Intelleflex to develop Cat 3 RFID Tags.